COTC027: Preclinical Comparison of Two Hypomethylating Nucleosides in Tumor-Bearing Dogs
Purpose:
This clinical trial led by the National Cancer Institute (NCI) assesses the safety and effectiveness of TdCyd and Aza-TdC, novel anticancer agents, when given to dogs with cancer. Studies in dogs with cancer will complement currently open human trials designed to test new doses and effects of this agent.
Participating Sites:
- Colorado State University, Ft. Collins, CO
- Purdue University, West Lafayette, IN
- The Ohio State University, Columbus, OH
- University of Illinois, Champaign, IL
- University of Georgia, Athens, GA
- University Of Missouri, Columbia, MO
- University of Wisconsin, Madison, WI
Sponsor: The National Cancer Institute
Study Numbers: 30 dogs will be enrolled
Eligibility Requirements:
- Histologically confirmed lymphoma or solid tumor
- Favorable performance status
- Naïve or recurrent disease
- Dogs must be more than 15kg
- Dogs cannot receive concurrent chemotherapy, radiation or angiogenesis for 2 weeks prior to study enrollment.
COTC029: Pilot assessment of BG34-200 in spontaneous canine cancers
Purpose:
The purpose of this study is to evaluate dose escalation of BG34-200 in dogs with cancer. We will be evaluating 1) evaluate the safety of BG34-200, and 2) evaluate the ability of BG34-200 to stimulate a patient’s immune system to detect and destroy cancer cells.
Participating Sites:
Sponsor: Case Western Reserve University
Study Numbers: 6-10 dogs will be enrolled
Eligibility Requirements:
- Histologically confirmed solid tumor malignancy
- Favorable performance status
- Naïve or recurrent disease
- Dogs must be more than 15kg
- Dogs cannot receive concurrent chemotherapy, radiation or angiogenesis for 2 weeks prior to study enrollment.